Loading…
← CockpitCompetitor Analysis › BIOA-B.ST BioArctic AB Class BOpen in the cockpit ↗

BioArctic AB Class BBIOA-B.STCompetitor analysis, valuation and peers

Sweden · SEK·Health Care›Pharmaceuticals: Major

Swedish biotech researching Alzheimer's disease treatments, partnered with Eisai on the approved drug lecanemab (Leqembi).

≈ A partnered Alzheimer's biotech with no direct large US peer (closest: Denali TherapeuticsMomentum weak 25
Mkt cap
$2.66B
US dollars, full cap
Free float
55%
of shares outstanding
$/day
$3.25M
20-day average traded
Fwd P/E
52.9×
forward earnings
ROIC−WACC
n/a
WACC 5.0%
Hurdle
-75 pp
Req g minus delivered
Next earnings
7 days
25 Nov 2026
Close · SEKSEK 304.40
1D-0.1%
1W-3.1%
1M+1.5%
3M-9.3%
6M-8.8%
YTD-2.1%
1Y+3.3%
ATR %2.9%
52w lowhigh16.5% off high

What BioArctic does

Swedish biotech researching Alzheimer's disease treatments, partnered with Eisai on the approved drug lecanemab (Leqembi).

Earns royalties on sales of Leqembi, which Eisai develops and markets, plus milestone payments as the drug reaches new markets, so BioArctic books the income without needing a global sales force. Eisai's approvals and commercial execution are therefore the main driver.

In one line: A partnered Alzheimer's biotech with no direct large US peer (closest: Denali Therapeutics.

Products and services

  • Lecanemab (Leqembi) royalty/partnership
  • Early-stage Alzheimer's/Parkinson's pipeline

Customers

  • Licensing partner Eisai
  • Ultimately Alzheimer's patients

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Neurodegenerative disease drug research

What could go right

  • Lecanemab global sales/royalty growth
  • New pipeline candidate progress

What could go wrong

  • Clinical trial failure risk on pipeline
  • Dependence on partner Eisai's commercial execution

Moat: narrow (IP / patents). Foundational antibody research and royalty rights on an approved Alzheimer's drug, though dependent on partner Eisai's commercialization.

Headquarters: Stockholm, Sweden · Founded: 2003 · Employees: 131

Named competitors

BioArctic at a glance

Size BioArctic (BIOA-B.ST) is a Sweden Health Care company (Pharmaceuticals: Major) with a market value of $2.66B, the 63rd largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 304.40 on 18 Nov 2026.

Performance Over six months the shares fell 8.8%, against -9.3% for the median peer and +2.8% for the Sweden market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue fell 46.1% over the last twelve months (peer median +5.1%); the operating margin is 22.1% (peer median 8.4%).

Valuation It trades at 52.9× forward earnings against a peer median of 27.6× (5th most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 26% a year for seven years (Req g). Recent delivered growth is +100%, so the hurdle is -75 pp: the price already allows for a slowdown.

Next results Next results expected around 25 Nov 2026 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026BIOA-B.ST 91Peer median 89
Six months, rebased to 100: BioArctic against the median of its 20 peers (local-currency closes).

BioArctic financials

Reported figures in SEK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueSEK 1.00BSEK 2.00BSEK 257MSEK 616MSEK 228M
Revenue growth—+677%-58%+170%—
Gross profitSEK 944MSEK 1.94BSEK 206MSEK 346MSEK 65.0M
EBITDAn/aSEK 1.40B-SEK 205MSEK 275MSEK 5.30M
Net incomeSEK 106MSEK 1.02B-SEK 177MSEK 229M-SEK 11.2M
Free cash flown/aSEK 1.42B-SEK 343MSEK 302M-SEK 44.4M
Capital expendituren/aSEK 10.2MSEK 26.6MSEK 7.44MSEK 12.7M
Total debtSEK 90.6MSEK 44.1MSEK 54.2MSEK 4.98MSEK 10.0M

Quarterly statements and history in the cockpit →

BioArctic competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%300199300558600518IDYA301301600380ALMPBH3696NEULANDLAB216208670013NAMS000250002773VCELPRGORGC301080BIOA-B.ST6-month return →1-month return →
Up and to the right = strong over both horizons. BioArctic is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%+150%25×50×75×300199300558301301600380ALMPBH3696NEULANDLAB08670013002773VCELPRGO301080BIOA-B.STRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. BioArctic is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%300199300558301301600380ALM369608670013PRGO301080BIOA-B.STGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. BioArctic is the large dot.

BioArctic competitors and peer comparison

Head to head with its named competitors (BIOA-B.ST vs LLY vs BIIB vs DNLI)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
BioArctic BIOA-B.ST$2.66B-9%-46%22%52.9×25.5%
Lilly (Eli) LLY$1.30T+36%+46%51%29.5×6.5%
Biogen BIIB$37.2B+34%+2%17%17.1×10.1%
Denali Therapeutics DNLI$2.95B-2%n/a-2,488%n/an/a

How BioArctic compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

BioArctic against its 20 peers (data as of 18 Nov 2026)
MeasureBIOA-B.STPeer medianRank in peer set
1-month return+1.5%-6.7%8th highest of 21
6-month return-8.8%-9.3%11th highest of 21
Distance from 52-week high-16.5%-38.0%5th highest of 21
Revenue growth (TTM)-46.1%+5.1%2nd lowest of 20
Operating margin22.1%8.4%5th highest of 20
Forward P/E52.9×27.6×5th most expensive of 16
Growth the price implies (Req g, 7 yrs)25.5%14.1%6th most demanding of 14
Growth delivered (Del g)+100.1%+6.5%highest of 14
Hurdle (Req g minus delivered)-74.5 pp+9.2 ppleast demanding of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
BioArctic BIOA-B.STSweden$2.66B-9%-46%22%52.9×25.5%+100.1%
Hybio Pharmaceutical 300199.SZChina$2.68B-8%+70%31%44.7×37.4%+6.1%
Betta Pharmaceuticals 300558.SZChina$2.70B-15%+16%11%38.0×23.2%+14.0%
Kangmei Pharmaceutical 600518.SSChina$2.61B-21%-6%-7%n/an/an/a
IDEAYA Biosciences IDYAUnited States$2.56B-11%-83%-1,267%n/an/an/a
Yili Chuanning Biotechnology 301301.SZChina$2.49B-24%-14%16%27.6×3.4%+4.8%
Joincare Pharmaceutical Group Industry 600380.SSChina$2.85B0%-12%18%15.5×-13.1%+2.4%
Almirall ALM.MCSpain$2.46B-13%+24%8%27.1×6.1%+6.5%
Prestige Consumer Healthcare PBHUnited States$2.40B+7%+5%25%10.6×2.3%+2.9%
InSilico Medicine Cayman TopCo 3696.HKHong Kong$2.40B-33%+153%-7%85.2×37.9%+22.9%
Neuland Laboratories NEULANDLAB.NSIndia$2.95B+28%+50%26%63.4×n/an/a
Keymed Biosciences 2162.HKHong Kong$2.39B+7%0%-73%18.2×n/an/a
China Medical System 0867.HKHong Kong$2.95B-15%+15%20%9.8×1.1%+2.7%
HUTCHMED (China) 0013.HKHong Kong$2.38B+14%-9%-6%35.9×47.0%+19.3%
NewAmsterdam Pharma NAMSUnited States$2.37B-45%-26%-900%n/an/an/a
Sam Chun Dang Pharm 000250.KSSouth Korea$2.36B-66%+23%7%n/an/an/a
Chengdu Kanghong Pharmaceutical 002773.SZChina$2.99B-1%-11%24%20.1×-3.3%+7.0%
Vericel VCELUnited States$2.99B+66%+25%8%68.3×46.5%+17.3%
Perrigo PRGOUnited States$2.35B+52%-4%5%6.7×14.1%+0.8%
Regencell Bioscience RGCUnited States$2.33B-83%n/an/an/an/an/a
Acrobiosystems 301080.SZChina$2.31B+65%+29%17%55.2×41.3%+27.7%

Questions

Who are BioArctic's main competitors?
Named competitors: Eli Lilly (donanemab) (LLY), Biogen (BIIB), Denali Therapeutics (DNLI). The cockpit's measured peer set (industry) also includes Hybio Pharmaceutical (300199.SZ), Betta Pharmaceuticals (300558.SZ), Kangmei Pharmaceutical (600518.SS), IDEAYA Biosciences (IDYA), Yili Chuanning Biotechnology (301301.SZ), Joincare Pharmaceutical Group Industry (600380.SS).
Is BioArctic expensive compared with its peers?
On forward p/e it trades at 52.9× against a peer median of 27.6×, 5th most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 26% a year for seven years (Req g). Recent delivered growth is +100%, so the hurdle is -75 pp: the price already allows for a slowdown.
How has BioArctic stock performed?
Over six months to 18 Nov 2026 the shares returned -8.8% against -9.3% for the median peer; over one year +3.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.